Effect of educational intervention on medication timing in Parkinson's disease: a randomized controlled trial

Katherine A Grosset, Donald G Grosset, Katherine A Grosset, Donald G Grosset

Abstract

Background: Medicine usage in Parkinson's disease patients is often imperfect, in particular irregular timing of medication. The effect of informing Parkinson's disease patients about the continuous dopaminergic hypothesis (to encourage regular medicine intake) on medication adherence and motor control was tested.

Methods: Patients were randomised either to the active group (receiving the intervention) or control group (no extra information). Antiparkinson medicine usage was monitored for 3 months before and after the intervention using electronic pill bottles which record the date and time of opening (MEMS, Aardex, Switzerland) and data used to calculate the percentage of doses taken at correct time intervals.

Results: 43 patients (52%) were randomised to active counselling, and 40 (48%) were controls (standard management). The intervention effect (difference in timing adherence pre- to post-intervention between the 2 groups) was 13.4% (CI 5.1 to 21.7), p = 0.002. Parkinson motor scores did not change significantly (active group 0.1, CI -3.4 to 3.7) versus controls (4.5, CI 1.6 to 7.1), p = 0.06.

Conclusion: Timing adherence, but not motor scores, improves by providing patients with extra information. Therapy timing is of potential importance in Parkinson's disease management.

Trial registration number: NCT00361205.

Figures

Figure 1
Figure 1
CONSORT diagram of study.
Figure 2
Figure 2
Adherence (maximum, upper quartile, median, lower quartile and minimum) against number of daily doses of antiparkinson medication. Timing adherence was lower with increasing number of daily doses (p

References

    1. Leopold NA, Polansky M, Hurka MR. Drug adherence in Parkinson's disease. Mov Disord. 2004;19:513–517. doi: 10.1002/mds.20041.
    1. Grosset KA, Bone I, Grosset DG. Suboptimal medication adherence in Parkinson's disease. Mov Disord. 2005;20:1502–1507. doi: 10.1002/mds.20602.
    1. Hughes DA, Bagust A, Haycox A, Walley T. Accounting for noncompliance in pharmacoeconomic evaluations. Pharmacoeconomics. 2001;19:1185–1197. doi: 10.2165/00019053-200119120-00001.
    1. Stocchi F, Vacca L, Ruggieri S, Olanow CW. Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. Arch Neurol. 2005;62:905–910. doi: 10.1001/archneur.62.6.905.
    1. Bezard E, Brotchie JM, Gross CE. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat Rev Neurosci. 2001;2:577–588. doi: 10.1038/35086062.
    1. Jenner P. Pathophysiology and biochemistry of dyskinesia: clues for the development of non-dopaminergic treatments. J Neurol. 2000;247 Suppl 2:II43–II50. doi: 10.1007/PL00007760.
    1. Grace AA. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience. 1991;41:1–24. doi: 10.1016/0306-4522(91)90196-U.
    1. Onn SP, West AR, Grace AA. Dopamine-mediated regulation of striatal neuronal and network interactions. Trends Neurosci. 2000;23:S48–S56. doi: 10.1016/S1471-1931(00)00020-3.
    1. Spencer SE, Wooten GF. Altered pharmacokinetics of L-dopa metabolism in rat striatum deprived of dopaminergic innervation. Neurology. 1984;34:1105–1108.
    1. Melikian C, White TJ, Vanderplas A, Dezii CM, Chang E. Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin Ther. 2002;24:460–467. doi: 10.1016/S0149-2918(02)85047-0.
    1. Girvin B, McDermott BJ, Johnston GD. A comparison of enalapril 20 mg once daily versus 10 mg twice daily in terms of blood pressure lowering and patient compliance. J Hypertens. 1999;17:1627–1631. doi: 10.1097/00004872-199917110-00017.
    1. Peveler R, George C, Kinmonth AL, Campbell M, Thompson C. Effect of antidepressant drug counselling and information leaflets on adherence to drug treatment in primary care: randomised controlled trial. BMJ. 1999;319:612–615.
    1. Henry A, Batey RG. Enhancing compliance not a prerequisite for effective eradication of Helicobacter pylori: the HelP Study. Am J Gastroenterol. 1999;94:811–815. doi: 10.1111/j.1572-0241.1999.00856.x.
    1. Rosen MI, Rigsby MO, Salahi JT, Ryan CE, Cramer JA. Electronic monitoring and counseling to improve medication adherence. Behav Res Ther. 2004;42:409–422. doi: 10.1016/S0005-7967(03)00149-9.
    1. Weber R, Christen L, Christen S, Tschopp S, Znoj H, Schneider C, Schmitt J, Opravil M, Gunthard HF, Ledergerber B. Effect of individual cognitive behaviour intervention on adherence to antiretroviral therapy: prospective randomized trial. Antivir Ther. 2004;9:85–95.
    1. O'Donnell C, Donohoe G, Sharkey L, Owens N, Migone M, Harries R, Kinsella A, Larkin C, O'Callaghan E. Compliance therapy: a randomised controlled trial in schizophrenia. BMJ. 2003;327:834. doi: 10.1136/bmj.327.7419.834.
    1. Becker LA, Glanz K, Sobel E, Mossey J, Zinn SL, Knott KA. A randomized trial of special packaging of antihypertensive medications. J Fam Pract. 1986;22:357–361.
    1. Gibb WR. Accuracy in the clinical diagnosis of parkinsonian syndromes. Postgrad Med J. 1988;64:345–351.
    1. Fahn S, Elton R, L, members of the UPDRS Development Committee . Recent develpoments in Parkinson's disease. 2. Florham Park,NJ, MacMillan Healthcare Information; 1987. Unified Parkinson's disease rating scale; pp. 153–163.
    1. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17:427–442.
    1. Schwab RS, England AC., Jr. Parkinson's disease: rehabilitation aspects. Rehabil Lit. 1961;22:326–336.
    1. Folstein M, F, Folstein S, E, McHugh P., R Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–198. doi: 10.1016/0022-3956(75)90026-6.
    1. Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, Leirer VO. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res. 1982;17:37–49. doi: 10.1016/0022-3956(82)90033-4.
    1. Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N. The Parkinson's Disease Questionnaire (PDQ-39): development and validation of a Parkinson's disease summary index score. Age Ageing. 1997;26:353–357. doi: 10.1093/ageing/26.5.353.
    1. Parkin SG, Gregory RP, Scott R, Bain P, Silburn P, Hall B, Boyle R, Joint C, Aziz TZ. Unilateral and bilateral pallidotomy for idiopathic Parkinson's disease: a case series of 115 patients. Mov Disord. 2002;17:682–692. doi: 10.1002/mds.10186.
    1. Fulmer TT, Feldman PH, Kim TS, Carty B, Beers M, Molina M, Putnam M. An intervention study to enhance medication compliance in community-dwelling elderly individuals. J Gerontol Nurs. 1999;25:6–14.
    1. Hugen PW, Langebeek N, Burger DM, Zomer B, van Leusen R, Schuurman R, Koopmans PP, Hekster YA. Assessment of adherence to HIV protease inhibitors: comparison and combination of various methods, including MEMS (electronic monitoring), patient and nurse report, and therapeutic drug monitoring. J Acquir Immune Defic Syndr. 2002;30:324–334.
    1. Bull SA, Hunkeler EM, Lee JY, Rowland CR, Williamson TE, Schwab JR, Hurt SW. Discontinuing or switching selective serotonin-reuptake inhibitors. Ann Pharmacother. 2002;36:578–584. doi: 10.1345/aph.1A254.
    1. Lee JY, Kusek JW, Greene PG, Bernhard S, Norris K, Smith D, Wilkening B, Wright JT., Jr. Assessing medication adherence by pill count and electronic monitoring in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. Am J Hypertens. 1996;9:719–725. doi: 10.1016/0895-7061(96)00056-8.
    1. Haynes RB, McDonald H, Garg AX, Montague P. Interventions for helping patients to follow prescriptions for medications. Cochrane Database Syst Rev. 2002:CD000011.
    1. Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL. How often is medication taken as prescribed? A novel assessment technique. JAMA. 1989;261:3273–3277. doi: 10.1001/jama.261.22.3273.
    1. Vrijens B, Belmans A, Matthys K, de Klerk E, Lesaffre E. Effect of intervention through a pharmaceutical care program on patient adherence with prescribed once-daily atorvastatin. Pharmacoepidemiol Drug Saf. 2006;15:115–121. doi: 10.1002/pds.1198.
    1. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23:1296–1310. doi: 10.1016/S0149-2918(01)80109-0.
    1. Cramer JA, Glassman M, Rienzi V. The relationship between poor medication compliance and seizures. Epilepsy Behav. 2002;3:338–342. doi: 10.1016/S1525-5050(02)00037-9.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe